CI
SPRY icon

CAZ Investments’s ARS Pharmaceuticals SPRY Stock Holding History

CAZ Investments’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Hold
2,000
– – ﹤0.01% 49
2026
Q1 		$16.1K Hold
2,000
– – 0.02% 38
2025
Q4 		$23.3K Hold
2,000
– – 0.04% 26
2025
Q3 		$20.1K Hold
2,000
– – 0.04% 27
2025
Q2 		$34.9K Sell
2,000
-500
-20% -$7.21K 0.2% 20
2025
Q1 		$31K Hold
2,500
– – 0.22% 21
2024
Q4 		$26K Hold
2,500
– – 0.04% 29
2024
Q3 		$36K Sell
2,500
-7,500
-75% -$89.2K 0.02% 28
2024
Q2 		$85K Buy
+10,000
New +$88.7K 0.03% 23

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

CAZ Investments's SPRY Position: Q2 2026 in Review

CAZ Investments held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 2,000 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #49.

CAZ Investments first reported a position in SPRY in Q2 2024 and has held it in 9 quarters since. The position peaked at $85K in Q2 2024. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • CAZ Investments held 2,000 shares of ARS Pharmaceuticals worth $16K as of Q2 2026.
  • CAZ Investments left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of CAZ Investments's portfolio in Q2 2026, its #49 holding.
  • CAZ Investments first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • CAZ Investments's ARS Pharmaceuticals position peaked at $85K in Q2 2024.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on CAZ Investments's 13F filing for Q2 2026, filed 13 Aug 2026.